Celanese Announces Acetyl Intermediates Price Increases in Asia

DALLAS & SHANGHAI--(BUSINESS WIRE)--$CE #Celanese--Celanese Corporation (NYSE: CE), a global technology and specialty materials company, will increase list and off-list selling prices for the following acetyl intermediate products. The price increases below will be effective immediately or as contracts otherwise allow, and are incremental to any previously announced increases.







Acetic Acid       ¥600       $100
Acetic Anhydride       ¥700       $125

About Celanese

Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese's global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,700 employees worldwide and had 2017 net sales of $6.1 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com or our blog at www.celaneseblog.com.

All registered trademarks are owned by Celanese International Corporation or its affiliates.


Celanese Corporation
Investor Relations
Surabhi Varshney, +1-972-443-3078
Media Relations – Global
W. Travis Jacobsen, +1-972-443-3750
Media Relations Asia (Shanghai)
Helen Zhang, +86 21 3861 9279
Media Relations Europe (Germany)
Jens Kurth, +49(0)69 45009 1574

Medline Expands Ability to Offset Carbon Footprint with Completion of Second Solar Installation in North America

Fifth installation worldwide marked by 1.1 Megawatt system in Rialto, California

NORTHFIELD, Ill.--(BUSINESS WIRE)--Medline today announced the completion of the second in a series of solar installations being undertaken to meet the organization’s growing sustainability goals. The 1.1 Megawatt system is estimated to generate power equivalent to 75 percent of that facility’s usage, significantly offsetting Medline’s dependency on the grid. EnterSolar, a national developer of solar programs for the commercial marketplace, worked with Medline to structure the design, engineering, and installation of the system, and will oversee the operations and maintenance of the system.

The power derived from more than 3,152 rooftop solar panels will provide meaningful environmental benefits for Medline, Rialto and the greater Southern California community at large. By using solar energy, environmental benefits are equivalent to saving nearly 92,000 gallons of gasoline a year or planting 772 acres of trees annually.

“For generations, Medline has worked shoulder to shoulder with healthcare customers to improve patient care. Corporate social responsibility helps us extend that impact even further by connecting the dots across the company and into the communities where we live, work and serve,” says Francesca Olivier, corporate social responsibility manager, Medline.

The completion of the Rialto facility system comes just one year after the completion of the first of two systems being installed at Medline’s Tracy, California distribution center. Medline is working with EnterSolar to add additional solar capacity to that facility, following a year of successful power generation.

“EnterSolar is proud to work with organizations of all sizes and missions. We’re exceptionally pleased to work with those organizations that demonstrate their commitment to sustainability in all of the regions they serve, and as such, we’re proud to partner with Medline to expand solar across their national portfolio,” said Peyton Boswell, managing director, EnterSolar.

Medline opened its first solar installation in July of 2016 at its distribution center in Aisai, Japan. On days with optimal conditions the 1,665 solar panels generate the majority of the energy needed to power the building, with the excess going back to the grid. The company also has systems in Australia, Germany and California and is working with EnterSolar to vet additional locations.

About Medline

Medline is a global manufacturer and distributor serving the healthcare industry with medical supplies and clinical solutions that help customers achieve both clinical and financial success. Headquartered in Northfield, Ill., the company offers 550,000 medical devices and support services through more than 1,400 direct sales representatives who are dedicated points of contact for customers across the continuum of care. For more information on Medline, go to www.medline.com or http://www.medline.com/social-media to connect with Medline on its social media channels.

About EnterSolar

EnterSolar is a leading national developer of solar photovoltaic solutions to the commercial marketplace. Unique in our combination of corporate business operations and solar expertise, we work with commercial enterprises to deliver optimal solar energy with compelling, long-term ROI. Expert in the dynamic legislative environment, EnterSolar provides clients with real-time guidance in order to best leverage tax credits and other financial incentives at federal, state and utility levels. Our clients include multi-national retailers, REITS, global manufacturers, and distributors, as well as family-owned businesses. The Company’s divisions include EnterSolarEDU, which helps schools, universities and non-profit organizations leverage solar and MaxSolar, which provides operations & maintenance, asset management and technical services for commercial systems nationwide. EnterSolar is headquartered in New York City with offices in New Jersey, Connecticut, California, Massachusetts, Maryland, and South Carolina. In its last ranking, Solar Power World ranked EnterSolar the leading (#1) solar developer in New York State and in the top 10 nationally. More information about EnterSolar, and its portfolio, can be found here.


Vivika Panagiotakakos, (847) 643-3311
Rachel Honig, 646.807.4604

Video Laryngoscopes – Growing Demand for Robot-assisted Laryngoscopy is an Emerging Trend | Technavio

LONDON--(BUSINESS WIRE)--#PatientMonitoringDevices--Technavio’s latest market research report on the global video laryngoscopes market provides an analysis of the most important trends expected to impact the market outlook from 2018-2022. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

According to Technavio market research analysts, the global video laryngoscopes market will grow at a CAGR of over 14% during the forecast period. Increasing M&A is a major factor driving the market’s growth.

The product portfolio of players increases with M&A, which helps in the product expansion and differentiation. Large players in the market are acquiring small players to access their key technologies and products, and form partnerships with distributors to increase their sales.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers

In this report, Technavio highlights the growing demand for robot-assisted laryngoscopy as one of the key emerging trends driving the global video laryngoscopes market:

Growing demand for robot-assisted laryngoscopy

Players in the market are developing innovative video laryngoscopes that offer greater accuracy and better support to operators owing to the advances in technology. The growing complications or risks associated with conventional and traditional surgeries are leading to higher demand for robot-assisted laryngoscopy. Characteristics of robot-assisted devices such as reliability will increase precision levels and have near-absolute geometric accuracy, which helps to reduce the workload of the specialists and improve the patient care. Robot-assisted airway management is attainable by using multipurpose surgical robotic systems.

“Players and research organizations are using robotics in a broad range of laryngoscopy procedures. The robotic arms can be used for successful intubation. The implementation of robotic devices leads to faster skill acquisition than manual procedures and also improves the performance and safety of the procedures. Therefore, the increase in demand for robot-assisted laryngoscopes will lead players to develop them, which will increase the market growth,” says a senior analyst at Technavio for research on patient monitoring devices.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Global video laryngoscopes market segmentation

This market research report segments the global video laryngoscopes market into the following applications (single-use devices and reusable devices), product (rigid video laryngoscopes and flexible video laryngoscopes), end-users (hospitals, clinics, and ASCs) and key regions (the Americas, APAC, and EMEA).

The rigid video laryngoscopes segment held the largest market share in 2017, accounting for nearly 85% of the market. The market share for this product is expected to increase nearly 2% by 2022. The rigid video laryngoscopes segment is expected to continue dominating the market and register the highest growth rate.

The Americas was the leading region for the global video laryngoscopes market in 2017, accounting for a market share of nearly 48%. By 2022, APAC is expected to see the highest growth rate. Some of the factors driving the market growth in these regions are the increasing incidence of cancer and other disorders related to the larynx.

Technavio’s best deals of the month!

Technavio supports Health for All campaign on this World Health Day with 20% savings on all reports in the Health and Wellness category for the entire month.


Celebrate International Astronomy Day by indulging in a whopping 30% savings on all reports in the Space category. Offer valid from 16th April for a limited period.


About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Global Spinal Surgery Devices Market – Increasing Prevalence of Spinal Disorders to Boost Growth | Technavio

LONDON--(BUSINESS WIRE)--#MedicalDevices--Technavio’s latest market research report on the global spinal surgery devices market provides an analysis of the most important trends expected to impact the market outlook from 2018-2022. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

According to Technavio market research analysts, the global spinal surgery devices market will grow at a CAGR of over 3% during the forecast period. The growing incidence of spinal disorders is a major factor driving the market’s growth.

The increasing prevalence of spinal disorders such as cervical spondylitis, DDD, excessive kyphosis, prolapsed intervertebral disc, spinal stenosis, herniated disc and vertebral fracture globally drives the global spinal surgery devices market. In most of these cases, surgery is the most effective treatment option.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers

In this report, Technavio highlights the increase in demand for spine biologics as one of the key emerging trends in the global spinal surgery devices market:

Increase in demand for spine biologics

Biologics are materials that alter the surrounding environment and affect the change in the environment through an active biological process that increases the cellular activity, differentiation, and growth. The popularity of biologics in spine fusion and spinal surgeries is increasing. Biologic materials are highly efficient and help in achieving successful arthrodesis. Pedicle screws and rods are often used in spine fusion surgeries. They help in providing spinal stabilization. However, they do not typically activate cellular growth, unlike biologic materials that attract more cells at the fusion site and actively increase bone formation and stimulate spinal fusion.

According to a senior analyst at Technavio for orthopedics and medical devices research, “Vendors are investing in research and designing novel biologic materials that can be helpful in restoring the normal spine function. For instance, NuVasive’s biologics portfolio includes integrated allogenic bone graft substitutes, extenders, ceramic, and synthetic bone grafts that are helpful in promoting bone fusion. Alphatec Spine offers Neocore Osteoconductive Matrix, a synthetic scaffold (β-TCP and collagen) that provides an effective core environment for bone growth. Similarly, stem cells have become a feasible option for future treatment of spinal disorders.”

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Global spinal surgery devices market segmentation

This market research report segments the global spinal surgery devices market by product (implants and instrumentation and spine biologics), by method (spinal fusion devices and spinal non-fusion devices), by procedure (open surgery and MIS), by end-user (hospitals, ASCs, and specialty orthopedic centers), and key regions (the Americas, APAC, and EMEA).

In 2017, the global spinal surgery devices market was dominated by the Americas with a market share of 72%, followed by EMEA and APAC. The US was a major revenue generator in the Americas. The driving factor for growth in the Americas is the increasing incidence of spinal disorders such as herniated discs, DDD, spondylolisthesis, prolapsed intervertebral disc, spinal stenosis, and osteoarthritis.

Technavio’s best deals of the month!

Technavio supports Health for All campaign on this World Health Day with 20% savings on all reports in the Health and Wellness category for the entire month.


Celebrate International Astronomy Day by indulging in a whopping 30% savings on all reports in the Space category. Offer valid from 16th April for a limited period.


About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

亚马逊工作室与Gillian Flynn签订全面协议,将制作《乌托邦》新剧集

屡获殊荣的畅销书作家和《消失的爱人》与《利器》的编剧Flynn将担任《乌托邦》一剧的创作人、执行制片人和剧集运作人。《乌托邦》新剧将在200多个国家和地区通过Prime Video独家播映。

西雅图--(BUSINESS WIRE)--NASDAQ: AMZN)— 亚马逊工作室(Amazon Studios)今天宣布,它已同意购买《乌托邦》(Utopia)整部剧集。该剧共9集,创作人是屡获殊荣的畅销书作家Gillian Flynn,她也是获得金球奖提名的《消失的爱人》(Gone Girl)和HBO备受瞩目的《利器》(Sharp Objects)两部影片的编剧。Flynn还与亚马逊工作室就电视版权达成了一项全面协议,让《乌托邦》成为双方合作的第一个电视项目。《乌托邦》将在200多个国家和地区通过Prime Video频道独家提供。

《乌托邦》是根据Dennis Kelly所写的同名英国版系列作品改编的。该剧由Endemol Shine North America、Endemol Shine Group英国制作工作室Kudos和亚马逊工作室联合制作。


亚马逊工作室另类系列负责人Nick Hall表示:“我们是Gillian Flynn惊悚作品的忠实粉丝。她编写的故事让观众一直处于悬念中,也打破了人们对剧中角色的期望。她将为Prime Video会员带来让他们难忘的精彩剧集,《乌托邦》肯定会在全球观众中间掀起一股热潮。”

Gillian Flynn表示:“《乌托邦》对我来说纯粹是创作灵感的迸发。Dennis Kelly的故事激活了我的思路,他的大胆想像让我得以完全闯进他的世界并在里面玩耍,再把它变成我自己奇异的荒野。《乌托邦》就是在黑暗、扭曲的叙事中探索能引起共鸣的问题——这是一个情节紧张、反映当今现状而又有点天方夜谭的编造!但是很有趣。”

Kudos首席执行官Diederick Santer表示:“Dennis Kelly和Kudos团队创作了一部独特、黑暗和紧张的英国惊悚片。让我们感到非常兴奋的是,Gillian Flynn已为全球的新观众进行了如此出色地重新创作。”

Flynn是《乌托邦》的创作者、执行制片人和剧集运作人,其他执行制片人包括Jessica Rhoades(Flynn与其在《利器》(Sharp Objects)中有过合作)、Sharon Hall、Karen WilsonDennis KellyDiederick Santer。Endemol Shine North America无剧本和有剧本电视节目总裁Sharon Levy将代表Endemol Shine负责拍摄。

Prime会员不需额外付费即可观看Prime Original的原创节目,用户可通过Prime Video应用在电视和联网设备(包括亚马逊Fire TV和移动设备)上欣赏,或在Amazon.com/originals上在线观看其他Prime Original原创系列。非Prime会员的合格客户可在www.amazon.com/prime上注册免费试用帐户。有关Prime Video兼容的全部设备列表,请访问www.amazon.com/howtostream。相关视频内容通过Prime Video应用和PrimeVideo.com向200多个国家和地区提供。

关于Prime Video

Prime Video是一种为客户提供最佳观看选择的高级点播娱乐服务——让用户在一个地方就能轻松找到他们喜欢的全部内容。

  • Prime会员服务的内容:在全球240多个国家和地区观看成千上万的流行电影和电视节目,包括我们屡获殊荣的Prime Original原创内容,如The Grand Tour、Maiseel Mrs. Maisel《诈欺担保人》(Sneaky Pete),奥斯卡获奖影片《海边的曼彻斯特》(Manchester by the Sea)和《推销员》(The Salesman),获得奥斯卡提名的《大病》(The Big Sick)、独家报道、体育直播、授权内容和用户发布内容
  • 通过Prime Video频道观看更多内容:Prime会员可以添加100多个频道,如HBO、SHOWTIME、STARZ、CBS All Access、Cinemax等——无需额外下载应用,也不需线缆连接。您只需要为您想要的内容付费,并且可随时取消。如要查看可用频道的完整列表,请访问www.amazon.com/channels
  • 租借或购买:所有亚马逊客户都可按需租赁或购买数以十万计的版权内容,包括新版电影和当前电视节目
  • 即时访问:使用Prime Video应用在电视、移动设备、Amazon Fire TV、Fire TV Stick、Fire平板电脑和Apple TV或以在线方式随时随地即时观看。有关所有兼容设备的列表,请访www.amazon.com/howtostream
  • 增强体验:4K超高清和高动态范围(HDR)兼容内容能为您提供最佳观看体验。利用IMDb支持的独家X-Ray通道可进入您喜爱的电影和电视节目的幕后。也可选择移动下载将其保存以供稍后离线观看。

除Prime Video外,Prime会员还可享受:亚马逊所有类别商品的无限快速免费送货选项,逾200万首歌曲和成千上万的Prime Music播放列表和电台,Prime Photos的安全照片存储,Prime Reading无限阅读,无限制地进入Audible Channels for Prime数字有声书目录,用Twitch Prime轮流选择免费数字游戏和游戏中的战利品,提前进入特定秒杀(Lightning Deals)活动,指定商品的独家购买权和折扣等等。 如要注册Prime或了解更多信息,请访问:Iwww.amazon.com/prime.


亚马逊遵循四项原则:客户至尚、热衷创新、追求卓越运营和长远思考。亚马逊首创推出的产品和服务包括:用户评论、一键购物、个人化推荐、Prime会员、亚马逊物流、AWS(亚马逊网络服务)、Kindle直接出版(Kindle Direct Publishing)、Kindle、Fire平板电脑、Fire TV、Amazon Echo和Alexa等。查询详情,请访问www.amazon.com/about并关注@AmazonNews





Early Access Launch Announcement of BAAM SQUAD: Zombies in Sweets Factory on Steam VR and Viveport on April 20, 2018 (PDT)

SEOUL, South Korea--(BUSINESS WIRE)--#5minlab--5minlab, best known for their VR debut ‘Toy Clash’ and won ‘Best VR’ award at Made With Unity(MWU) Korea event in 2018, announced that they released their second VR franchise called ‘BAAM SQUAD’ but this time, with a seasoned co-op multiplayer feature and FPS element.

Purchase on Steam
Purchase on Viveport
Official Trailer

‘BAAM SQUAD’ takes you to an abandoned sweets factory where it has been overrun by a zombie outbreak. With up to four players to co-op together, the goal is to roam around the factory while defending yourselves from streams of zombies looking for blood and sugar. Player has to keep them at a safe distance with an arsenal of weapons while keeping the electricity running to maintain the power for elevators, doors, vending machines and other useful traps.

The game has undergone an open beta during April 13 - 19 via their official discord channel, with more than 450 users participated and enjoyed pretty much of the game contents, ended up leaving their names on a global leaderboard.

Here are the key features of ‘BAAM SQUAD: Zombies in Sweets Factory’.

  • Journey into Sweets Factory – Complete with jelly trampolines, conveyor oven and hot chocolate falls. Vending machines are everywhere selling buffing snacks and mysterious sodas.
  • Free Exploration – Use controller to walk or run without motion-sickness, teleportation and space restriction.
  • Weapons – From classic pistol to Sci-Fi laser gun. Collect all 10+ weapons and upgrade them to MAX level, optimizing your chance to survive longer.
  • Online Co-op – Play with friends or other players around the world. Up to four players allowed.
  • Global leaderboard – Mark your name on the top by killing as many zombies as you can. Headshot is the key to get high score and saving bullets.
  • Various Hand Interaction – Shoot guns, pull levers, throw objects and much more. You can also give hands to your friends who are bleeding out.

More information about the game can be found in their official website and discord channel where you can expect the devs to interact with players 24/7.

The game will be available at a price of 14.99 USD during its early access period. Eric Song, the lead developer of BAAM SQUAD stated that the team is “going to use Steam community and discord to interact with players while putting an effort to update more mobs and maps, perhaps more cool weapons too”.


Eric Song, +82 10 3129 3656

新研究调查Masimo SpHb®在术后红细胞(RBC)输血最佳实践中的功用

葡萄牙里斯本--(BUSINESS WIRE)--(美国商业资讯) -- Masimo (NASDAQ: MASI)今天发布了患者血象管理、止血和栓塞促进网络(NATA) 2018年度年会上呈报的一份摘要中的发现,该研究的研究人员调查了Masimo无创连续血红蛋白(SpHb®)作为术后患者血象管理(PBM)的一部分在支持和提升红细胞(RBC)输血最佳实践中的功用1

该研究中,雷焦艾米利亚AUSL-IRCCS输血医学科和意大利帕尔马大学内外科的Baricchi教授及其同事寻求评估3年期间(2013-2015)术后RBC输血在患者血象管理(PBM)项目部署前后的适宜性。PBM政策由3个月的培训组成,然后采用Masimo Radical-7®脉搏碳氧-氧饱和度仪®上的Masimo SpHb对患者血红蛋白进行无创连续治疗现场(POC)监测。在引进PBM政策之前,对168例患者的RBC输血适宜性开展初步稽查。政策落地后,对205例患者开展终局稽查。为了确定输血适宜性,研究者采用了意大利输血医学和免疫血液学会(SIMTI)确立的指南。

研究人员发现,在引进PBM政策之前,37.7%的RBC输血是适宜的。引进PBM政策之后,包括采用Masimo SpHb开展无创连续血红蛋白监测之后,他们发现,65.4%的RBC输血是适宜的,输血适宜性有大幅提高。



@MasimoInnovates | #Masimo


  1. Baricchi R, Marraccini C, Merolle L, Berni P, Bonini A, Mazzi A, Pertinhez T.A., and Di Bartolomeo E. Patient blood management: transfusion appropriateness in the postoperative period. Proceedings from the 2018 NATA Annual Meeting, Lisbon, Portgual. #P30. (患者血象管理:术后阶段的输血适宜性。2018年度NATA年会会议论文集,葡萄牙里斯本。#P30。)


Masimo (NASDAQ: MASI)是创新的无创监测技术的全球领先者。我们的使命是改善患者转归并降低治疗成本。1995年,公司推出了Masimo SET®移动和低灌注下测量(Measure-through Motion and Low Perfusion™)脉搏氧饱和度仪,多项研究已显示,该仪器可大幅减少假警报、并准确监测真警报。研究显示,Masimo SET®可帮助临床医生减少早产新生儿的重度视网膜病变1、改善新生儿的CCHD筛查2,在用于术后病房的Masimo Patient SafetyNet™*连续监护时,可减少快速响应动员和成本3,4,5。Masimo SET®据估计已应用于全世界领先医院及其他医疗机构中超过1亿的患者6,是《美国新闻与世界报道》2017-18年最佳医院荣誉榜排名前20位医院中17家医院采用的主要脉搏氧饱和度仪7。2005年,Masimo推出了rainbow®脉搏碳氧-氧饱和度仪技术,实现了以往只能侵入性测量的血液成份的无创连续监测,包括总血红蛋白(SpHb®)、氧含量(SpOC™)、碳氧血红蛋白(SpCO®)、高铁血红蛋白(SpMet®)、脉搏灌注变异指数(PVi®)及最新的氧储备指数(ORi™),此外还有SpO2、脉率和灌注指数(Pi)。2014年,Masimo推出了Root®,这是一种直观的患者监测和互通平台,搭载Masimo Open Connect® (MOC-9®)界面,使其他公司能够用新特性和测量功能来增强Root。Masimo同时在mHealth领域凭借Radius-7®可穿戴患者监护仪、用于智能手机的iSpO2®脉搏氧饱和度仪和MightySat™指尖脉搏氧饱和度仪等产品发挥积极的主导作用。欲了解Masimo及其产品的进一步信息,请访问www.masimo.com。有关Masimo产品的已发表临床研究,请访问http://www2.masimo.com/evidence/featured-studies/feature/

ORi未获得FDA 510(k)核准,未在美国上市。

*Patient SafetyNet商标由University HealthSystem Consortium授权使用。


  1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb; 100(2):188-92. (通过临床实践转变和SpO2技术预防早产儿视网膜病变。《儿科学杂志》2011年2月;100(2):188-92.)
  2. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338. (脉搏氧饱和度筛查对导管依赖型先天性心脏病检出的影响:瑞典39,821例新生儿前瞻性筛查研究。《英国医学杂志》2009年1月8日;338.)
  3. Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287. (脉搏氧饱和度监测对救治事件和重症监护室转床的影响:前后巧合研究。《麻醉学》2010; 112(2):282-287.)
  4. Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012. (术后监护–达特茅斯经验。《麻醉患者安全基金会通讯》2012年春夏刊。)
  5. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul; 42(7):293-302. (普通监护病房的监测监护管理:策略、设计和执行。《质量与患者安全联合委员会杂志》2016年7月;42(7):293-302.)
  6. 估计值:Masimo存档数据。
  7. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview


本新闻稿包含美国1933年《证券法案》第27A条和1934年《证券交易法案》第21E条以及1995年《私人证券诉讼改革法案》所定义的前瞻性陈述。这些前瞻性陈述包含有关Masimo SpHb®潜在功效的各类陈述,等等。这些前瞻性陈述基于对影响我们的未来事件的当前预期,并受到风险和不确定性的制约,所有的风险和不确定性均难以预测,其中多数超出我们的掌控,并有可能导致我们的实际结果与我们的前瞻性陈述中表述的结果大相径庭和截然相反,其原因是各类风险因素,包括但不限于与下列因素相关的风险:我们对涉及临床结果可重复性的假设;我们对Masimo独特的无创测量技术(包括Masimo SpHb)的信念,即这些技术可对积极的临床转归及患者安全性做出贡献;与我们相信Masimo无创医学突破可提供具有成本效益的解决方案和独特优势的信念相关的风险;以及我们向美国证券交易委员会(“SEC”)递交的最新报告中“风险因素”章节中讨论的其他因素,这些报告可从SEC的网站www.sec.gov上免费获得。尽管我们相信我们的前瞻性陈述中反映的预期是合理的,但我们并不知道我们的预期将来能否被证明正确。本新闻稿包含的所有前瞻性陈述完全符合前述警示性声明。谨此提醒您注意不要对这些前瞻性陈述给予不适当的依赖,这些陈述仅适用于今日。除非在适用的证券法律可能的要求下,我们没有任何责任来更新、修订或澄清这些陈述或是我们向SEC递交的最新报告中包含的“风险因素”,无论是作为新信息、未来事件的结果还是其他事项的结果。



Evan Lamb

A.M. Best Affirms Credit Ratings of Ansvar Insurance Limited

HONG KONG--(BUSINESS WIRE)--A.M. Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” of Ansvar Insurance Limited (Ansvar) (Australia). The outlook of these Credit Ratings (ratings) is stable.

The ratings reflect Ansvar’s balance sheet strength, which A.M. Best categorizes as very strong, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management.

The balance sheet strength assessment mainly reflects Ansvar’s low business net retention and moderate underwriting leverage. In addition, while the company’s investment portfolio continues to be invested in cash and high-grade fixed-interest securities, the average duration of its bond portfolio and net claims liabilities is very well-matched. Given Ansvar’s modest capital size, its exposure to property/casualty risks that carry relatively high policy limits represents a major risk factor. Nevertheless, this risk is mitigated partially by an appropriate reinsurance program that has very conservative levels of retention limits.

In response to poor underwriting results from 2010 to 2012, Ansvar exited its unprofitable personal lines business and implemented various measures to remediate the performance of its commercial book. Despite a reduced revenue base following these remedial actions, the company has consistently generated operating profits over the past five years, driven mainly by a steady stream of investment income and a stable net claims ratio of approximately 50%. Similar to a number of its peers, the company’s high expense ratio has been the major overhang on operating performance. Nevertheless, A.M. Best believes that, as Ansvar continues to focus on strong customer retention and pursues profitable growth of its niche businesses, its operating results will remain positive and gradually improve over time.

Ansvar is a niche insurer that underwrites general insurance products for its target customer groups in Australia, which includes faith, community service organizations, care, education, and property owners including heritage. Its core product offerings are property insurance, liability insurance (including financial lines insurance) and accident covers. While Ansvar has a long-established presence in some niche segments, A.M. Best believes this advantage is offset somewhat by the company’s limited control over distribution and a reliance on the non-affiliated broker channel to distribute its products.

Given its status as a stable operator within a niche segment, Ansvar’s risk profile shows high business concentration risk. Nevertheless, A.M. Best considers Ansvar’s risk management capabilities to be aligned appropriately with its risk profile. This is underpinned by the company’s strict underwriting controls, prudent reserving and low business retention, as well as by various strategic initiatives to develop new business opportunities within its target customer groups.

The stable outlooks reflect A.M. Best’s expectation that Ansvar will maintain positive operating results, supported by stable revenue growth, steady claims ratios and an expense ratio that is expected to decline gradually over time. Negative rating actions could occur if Ansvar fails to meet its profitability targets due to competitive pressures, or if there are material adverse deviations from the budgeted loss and expense ratios.

Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication.

This press release relates to Credit Ratings that have been published on A.M. Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see A.M. Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Understanding Best’s Credit Ratings. For information on the proper media use of Best’s Credit Ratings and A.M. Best press releases, please view Guide for Media - Proper Use of Best’s Credit Ratings and A.M. Best Rating Action Press Releases.

A.M. Best is the world’s oldest and most authoritative insurance rating and information source. For more information, visit www.ambest.com.

Copyright © 2018 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.


A.M. Best
Jason Shum, +65 6303 5020
Associate Director, Analytics
Chi-Yeung Lok, +65 6303 5016
Director, Analytics
Christopher Sharkey, +1 908-439-2200, ext. 5159
Manager, Public Relations
Jim Peavy, +1 908-439-2200, ext. 5644
Director, Public Relations


  • 第三届Horasis全球会议将汇集来自70多个国家代表企业、政府、学界和民间的600多名领导人
  • 会议的主题是激励我们的未来

葡萄牙卡斯凯什--(BUSINESS WIRE)--(美国商业资讯)--致力于激励我们未来的全球愿景社区Horasis宣布,将于5月5日至8日在葡萄牙CASCAIS举办2018年Horasis全球会议。由来自70个国家的600多名世界领导人组成的Horasis社区将齐聚一堂,讨论今年的主题“激励我们的未来”。



这次活动将吸引全球最杰出领导人参加。与会的政治领导人包括马拉维总统Peter Mutharika,亚美尼亚总统Armen Sarkissian,佛得角总理Ulisses Correia e Silva,丹麦财政部长Kristian Jensen约旦El Hassan bin Talal王子殿下,埃及前副总统、诺贝尔和平奖获得者Mohamed ElBaradei等等。参会的世界最受尊敬的各大公司首席执行官和代表包括:高盛国际董事长Jose Manuel Barroso,Quantum Leaps Corporation首席执行官Nobuyuki Idei,McLarty Associates副董事长John D. Negroponte等。

Horasis董事长Frank-Jürgen Richter表示:“我们Horasis认为,明确全球性相关问题和发展战略需要思想领导和点对点的人际网络。许多领导人已经确认参加本次会议,我期待看到今年的共同努力如何激励我们的未来。”


Cascais市长Carlos Carreiras表示:“我们以成功而持久的确定性良好合作关系欢迎Horasis的举行。我们在过去的几年中已经证明,不仅Horasis是世界上最著名的论坛之一,而且Cascais是它的最佳举办地。”






Frank-Jurgen Richter博士,+41 79 305 3110

PSE: APM Forum 2018 Focus on Digitalisation for the Process Industries

Key role of deep process knowledge in digital design and digital operations

LONDON--(BUSINESS WIRE)--#APMF--At the 2018 Advanced Process Modelling (APM) Forum this week, process industry organisations presented on digital design and operations applications ranging from accelerating development of the next generation of pharmaceuticals to realising millions of dollars per year in increased profit for large process plants.

Introducing the conference, Prof. Costas Pantelides, MD of conference host Process Systems Enterprise (PSE), described the current wave of digitalisation as the culmination of many years of advanced modelling and IT development. “This is a time of extraordinary opportunities for the process industries” he said.

Keynote speaker Mathias Oppelt of Siemens described how high-fidelity process models containing deep process knowledge bring a new level of power to digitalisation initiatives being delivered by automation companies. Siemens later demonstrated digital twin technology for an ethylene plant, implemented using PSE’s gPROMS Olefins software. SABIC showed how new online technologies improved yield by 2% at a large petrochemicals plant, representing tens of millions of dollars per year, and BASF described how digital technologies that combine data and models are enabling an enhanced innovation approach with strong focus on customers and markets.

Keynote speaker Suracha Udomsak, R&D director at SCG Chemicals, said “APM is a key element of our Digital Manufacturing platform. It accelerates innovation by making the development workflow faster, cheaper and safer”.

On the Formulated Products side, keynote speaker Ben Weinstein of Procter & Gamble described how a strategic decision many years ago to back a digital design approach has accelerated innovation across P&G.

Pharma keynote Neil Hodnett of GSK showed how system modelling is applied to accelerate development and transfer of robust manufacturing processes, particularly in the move to continuous processing, through the use of virtual DoEs for in-silico QbD.

Roche, Pfizer, Ferring, Novartis, Sandoz, UCB, Syngenta, Danone and FrieslandCampina described benefits of applying advanced mechanistic modelling to improve drug product manufacture, increase R&D efficiency and reduce risk in scale-up and tech transfer.

Pantelides adds “a common theme is that it is now possible to easily capture deep process knowledge in the form of predictive models, then use these within a digitalisation framework to generate value at every step”.


Process Systems Enterprise
Kate Burness
Editors: www.psenterprise.com/news/pr180420


K. Guru Gowrappan加入管理团队以加速公司的发展和全球扩张

纽约--(BUSINESS WIRE)--(美国商业资讯)--Verizon (NYSE, Nasdaq: VZ)旗下子公司Oath今天宣布,K. Guru Gowrappan将加入该公司担任总裁兼首席运营官。Guru曾任阿里巴巴集团全球董事总经理。他在Oath成立的第二年加入,将在领导公司的运营和全球发展战略方面发挥关键作用。Guru将发挥他在全球范围进行业务扩张的经验,与首席执行官Tim Armstrong以及Oath和Verizon领导团队合作,巩固Oath作为美国在线(AOL)、BUILD、HuffPost、MAKERS、TechCrunch、雅虎邮箱、雅虎新闻和雅虎体育等值得信赖的媒体和技术品牌的强大地位。他将向Armstrong汇报工作。

Oath首席执行官Tim Armstrong表示:“Oath在世界最具颠覆性的经济领域为全球十亿消费者和最重要的品牌提供服务。聘请Guru担任总裁兼首席运营官将加快实现我们的清晰愿景:成为未来数年的增长平台。我们拥有由数字品牌和平台组成的超乎寻常的生态系统,有世界最佳移动公司Verizon的支持,还有以凝聚最优秀的外部和内部人才为中心的公司文化——随着Guru的加入和帮助引领公司走向未来,这些优势会变得更加强大。”







Verizon Communications Inc. (NYSE, Nasdaq: VZ)总部位于纽约市,2017年营收为1,260亿美元。公司运营着美国最可靠的无线网络和全美主要的全光纤网络,并向全球企业提供集成解决方案。



Allison Butler



ニューヨーク--(BUSINESS WIRE)--(ビジネスワイヤ) -- ベライゾン(NYSE、Nasdaq: VZ)子会社のオースは本日、当社の社長兼最高執行責任者(COO)としてK・グル・ゴウラパンを迎えることを発表します。ゴウラパンはこれまで、アリババグループのグローバルマネジングディレクターを務めていました。オースが設立2年目となる中、ゴウラパンは当社の運営と世界的成長戦略を指揮する極めて重要な役割を担うことになります。ゴウラパンは世界で事業を拡大してきた経験を生かし、ティム・アームストロング最高経営責任者(CEO)やオースおよびベライゾンの経営陣と協力し、AOL、ビルド、ハフポスト、メイカーズ、テッククランチ、ヤフーメール、ヤフーニュース、ヤフースポーツなど、信頼されるメディア/技術ブランドを擁する巨大企業としてのオースの地位を固めていきます。ゴウラパンはアームストロング直属となります。








ベライゾン・コミュニケーションズ(NYSE、Nasdaq: VZ)はニューヨーク市に本社を置いており、2017年に1260億ドルの売上高を上げました。当社は米国で最も信頼性の高い無線ネットワークと米国の有力オールファイバーネットワークを運営し、世界の企業に総合的ソリューションを提供しています。



Allison Butler

Praxair Signs Long-Term Agreement to Supply Samsung Electro-Mechanics in Busan, South Korea

DANBURY, Conn.--(BUSINESS WIRE)--$PX #PraxairInc--Praxair, Inc. (NYSE:PX) today announced it has signed a long-term agreement to supply industrial gases to Samsung Electro-Mechanics (SEM), one of the world’s largest MLCC (Multi-Layer Ceramic Capacitors) manufacturers.

Praxair has been supplying nitrogen to SEM’s manufacturing facility in the Noksan Industrial Complex in Busan since 2001. The new air separation plant, which will be built, owned and operated by Praxair, will supply an additional 425 tons per day of nitrogen to support SEM’s world-class MLCC manufacturing expansion. The new plant will start up in 2019, further increasing Praxair’s density in the southeast region of South Korea.

"Praxair has been reliably supplying Samsung’s facility in Noksan for over 17 years. We are proud to strengthen this longstanding relationship with SEM and look forward to supporting their ongoing growth and expansion," said B.S. Sung, president of Praxair Korea.

About Praxair

Praxair, Inc. is a leading industrial gas company in North and South America and one of the largest worldwide. With market capitalization of approximately $40 billion and 2017 sales of $11 billion, the company employs over 26,000 people globally and has been named to the Dow Jones® World Sustainability Index for 15 consecutive years. Praxair produces, sells and distributes atmospheric, process and specialty gases, and high-performance surface coatings. Our products, services and technologies are making our planet more productive by bringing efficiency and environmental benefits to a wide variety of industries, including aerospace, chemicals, food and beverage, electronics, energy, healthcare, manufacturing, primary metals and many others. For more information about the company, please visit our website at www.praxair.com.


Praxair Media:
John Puskar, 203-837-2448
Praxair Investors:
Juan Pelaez, 203-837-2213



替代和改善已然成功的PGT Healthcare合资企业

辛辛那提--(BUSINESS WIRE)--(美国商业资讯) -- 宝洁公司(NYSE:PG)今天宣布签署协议,以近34亿欧元的收购价收购德国达姆施塔特默克集团(Merck KGaA)的消费者健康业务。


宝洁董事长兼总裁和首席执行官David Taylor表示:“我们看好非处方药保健市场稳定的、根基辽阔的增长,欢迎德国达姆施塔特默克集团的消费者健康产品阵容和员工加入到宝洁大家庭中。”


宝洁公司全球保健业务集团总裁Steve Bishop表示:“过去数年来,本公司保健业务实现了稳步增长,为股东创造了巨额价值。德国达姆施塔特默克集团的消费者健康业务带来了一批强势品牌、产品和能力,提供了有吸引力和互补性的布局,将进一步助力本公司现有领先品牌的不断增长。”

收购德国达姆施塔特默克集团的消费者健康业务,将替代和改善宝洁与Teva Pharmaceutical Industries (NYSE: TEVA)之间非常成功的PGT Healthcare合资企业,PGT将于2018年7月1日终止营业,该终止营业有待监管部门的核准。

PGT Healthcare合资企业自成立以来,实现了不成比例的增长上限和下限,在50多个国家确立了重大布局。但近期一项评审显示,Teva和宝洁认为双方之间的优先与策略不再一致,同意了终止该合作伙伴关系对双方均有利的条款。PGT产品资产将回归各自的母公司,重新设立独立的非处方药业务。

德国达姆施塔特默克集团的消费者健康业务价值10亿美元,过去2年来增长6%,提供品种多样的非处方药产品,用于缓解肌肉痛、关节痛、背痛、感冒、头痛,以及支持躯体活动性和移动性。主要品牌包括Neurobion、Dolo-Neurobion、Femibion、Nasivin、Bion3、Seven Seas、Kytta等等。上述产品主要在欧洲、拉丁美洲和亚洲销售。

宝洁全球个人保健业务总裁Tom Finn表示:“德国达姆施塔特默克集团消费者健康业务的上述领先品牌和出色员工将极大充实本公司的个人保健业务。此次收购提供的能力和产品阵容规模,对于本公司不借助保健合作伙伴而独立开展全球性非处方药业务并取得成功是必不可少的,可帮助我们继续推动宝洁的销售和利润增长。”

德国达姆施塔特默克集团董事长兼首席执行官Stefan Oschmann表示:“剥离本公司的消费者健康业务是本公司专注于保健、生命科学和高性能材料领域创新驱动业务战略的重要步骤。它清晰地表明了我们对积极塑造本公司作为领先的科技公司的产品阵容有不懈的承诺。消费者健康是一项强劲的业务,值得获得有利于其未来发展的尽可能的最佳机会。宝洁是一家强大的、获得高度认可的公司,它具备推进该业务走向成功所必需的规模。”

德国达姆施塔特默克集团董事、消费者健康业务首席执行官Belén Garijo表示:“宝洁的全球规模以及对消费者健康和福祉的战略兴趣为加快增长提供了绝佳的基础,可发挥本公司团队能力的优势,扩大消费者健康业务的利润。两家公司的已上市产品阵容、后续产品管线和地域布局具有高度互补性。通过此次交易,本公司将继续严格贯彻本公司的战略,以成为全球性的专科产品创新者,向患者提供突破性的药品。”



宝洁服务全球消费者。该公司拥有最强大的值得信赖的优质领先品牌组合之一,这些品牌包括:好自在®(Always®)、香必飘®(Ambi Pur®)、碧浪®(Ariel®)、Bounty®、Charmin®、佳洁士®(Crest®)、Dawn®、Downy®、Fairy®、纺必适®(Febreze®)、Gain®、吉列®(Gillette®)、海飞丝®(Head & Shoulders®)、兰诺®(Lenor®)、玉兰油®(Olay®)、欧乐-B®(Oral-B®)、帮宝适®(Pampers®)、潘婷®(Pantene®)、SK-II®、汰渍®(Tide®)、Vicks®和护舒宝®(Whisper®)。宝洁品牌在全球约70个国家设有业务部门。请访问http://www.pg.com 浏览有关宝洁及其品牌的最新新闻和信息。






Heather Huff, +1-513-622-1810

Tressie Rose, +1-513-983-4929

John Chevalier, +1-513-983-9974

Meredith-Springfield Associates, Inc., is First North American Blow Molder to Acquire Latest ISBM Technology from Japan’s Aoki Technical Laboratory, Inc.

The AL-500LL-50S is the newest model of an injection stretch-blow molding machine (ISBM) that Meredith-Springfield will use to produce a new line of disposable plastic drinkware

LUDLOW, Mass.--(BUSINESS WIRE)--#Aoki--Meredith-Springfield became the first North American company to purchase the latest iteration of an injection stretch-blow molding machine (ISBM) from Japan’s Aoki Technical Laboratory, Inc., which will enable Meredith-Springfield to economically produce a new product line of premium PET drinkware.

The AL-500LL-50S cuts molding cycle times by as much as 45 percent and production volume is either maintained or it more than doubles on a yearly basis, depending on the size of the container. The machine is also more energy efficient, saves space and reduces equipment and production costs through downsizing of the unit.

The drinkware that Meredith-Springfield will produce is for premium, single-serve use at hotels, conventions, outdoor and poolside venues; anywhere premium cocktails and beverages are served but where using glass poses a safety hazard. The line includes stemless wine and Champagne glasses, carafes, pilsner glasses and other uniquely shaped cocktail glasses.

“This is a game-changing moment for Meredith-Springfield as the acquisition of the AL-500LL-50S creates economic, energy, equipment and production efficiencies for us as we produce a new product line,” said Mel O’Leary, Meredith-Springfield President and Chief Executive Officer. “It is differentiating technology.”

Eiji Nishizawa, President of Aoki Laboratory America, added: “Our high-speed mold release technology enables the molding of a bottle at a cycle that is faster than previous versions of our machines while delivering the same quality.” Nishizawa explained that his company utilizes molding technologies that enable the production of plastic containers with minimum expenditure of energy, including Direct Heatcon®, an original single-stage, three-station system that represents the ultimate in energy-saving molding technology.

“We depend on the Earth for our existence, so at Aoki, we commit ourselves to the protection of our natural environment and the advancement of international culture that makes use of plastic containers,” Nishizawa said.

Aoki will be exhibiting Meredith-Springfield’s sister machine at the National Plastics Exhibition in Orlando, Florida, in May. At the Aoki booth, attendees will see live demonstrations of a 200 mL, 24 gram PET bottle having a 20MM neck finish and cycling 6 cavities at an unprecedented 8.5 second cycle. Existing technology achieves a 19.1 second cycle on the same bottle currently so the production is more than doubled.

Meredith-Springfield will exclusively produce PET articles with its machine. However, it is equipped to run almost any polymer which can be blow molded such as HDPE, PP or Tritan®. For some of the drinkware, Meredith-Springfield will use its patent-pending, proprietary post-molding lip forming process to create a glass-like bead rim on the top openings.

O’Leary said less tooling costs associated with the AL-500LL-50S, “allows for a price point that will enable customers with lower volumes or smaller tooling budgets to enjoy the benefits of one-step stretch blow molding previously achievable only with a major tooling expenditure.”

About Meredith-Springfield Associates, Inc.
An SQF-certified plastic extrusion and injection stretch blow molding manufacturing and engineering company in Ludlow, Mass., Meredith-Springfield has built a reputation for providing superior, high-quality finished products and a hassle-free experience to companies across the globe. The company’s core competencies include project management of extrusion blow molded articles from concept through commercialization, and creating process solutions to enable optimal manufacturing of the most difficult articles. Meredith-Springfield offers the latest technology for molding PET and other resins to the existing client base and can take advantage of other global opportunities. Clients include American Distilling Inc., B&G Foods, Inc., Clorox, Elizabeth Arden, Jarden Home Brands, OmniMax, PepsiCo, and Reebok. These are just a few of the companies who in the past, or at present, enjoy partnerships with Meredith-Springfield. Resin capabilities include HDPE, PP, PVC, PA, PET, EPET, TPE, TPU, ABS, LDPE and Fluoropolymers. Serving the medical, packaging, industrial, HBA, and food industries, Meredith-Springfield consistently demonstrates its capabilities in world-class product design and manufacturing and deepens its national and international relationships. Meredith-Springfield is also a consistent referral for companies of all sizes who need test-market quantities of custom blow molded prototype samples for research and development (R&D) and for “out-of-the box” concept development. For more information, please visit meredithspringfield.com.

About Aoki Technical Laboratory, Inc.
Founded in 1976 by Mr. Katashi Aoki, and based in Nagano, Japan, Aoki Technical Laboratory plans, develops, manufactures and sells injection stretch-blow molding machines, molds, auxiliary equipment and parts for molding plastic bottles. The company has offices and representatives in Chicago, Brazil, Mexico, Germany, Singapore, Shanghai and Guangdong, China, Thailand, Spain, and the United Kingdom. The company was the first to produce One-Step ISBM technology and it has sold 3,600 of its current machine platforms to users worldwide. Aoki has 350 employees globally supporting sales, machine installations and service. For more information, please visit aokitech.co.jp/english/offices.


For Meredith-Springfield Associates, Inc.
Lisa Twarog, 413-787-1133